United Therapeutics (NASDAQ:UTHR) issued its earnings results on Wednesday. The biotechnology company reported $2.41 EPS for the quarter, meeting the Zacks’ consensus estimate of $2.41, MarketWatch Earnings reports. United Therapeutics had a return on equity of 14.90% and a net margin of 30.04%. The company had revenue of $362.00 million during the quarter, compared to the consensus estimate of $339.97 million. During the same period in the previous year, the firm posted $3.63 earnings per share. United Therapeutics’s quarterly revenue was down 3.1% compared to the same quarter last year.
NASDAQ:UTHR opened at $111.47 on Friday. United Therapeutics has a 12-month low of $75.58 and a 12-month high of $127.79. The company has a quick ratio of 8.46, a current ratio of 7.43 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $5.00 billion, a PE ratio of 11.65 and a beta of 0.86. The firm has a 50-day moving average price of $117.48 and a 200 day moving average price of $106.45.
In related news, CEO Martine A. Rothblatt sold 10,000 shares of the stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $117.91, for a total value of $1,179,100.00. Following the completion of the transaction, the chief executive officer now owns 10,140 shares of the company’s stock, valued at $1,195,607.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Tommy G. Thompson sold 3,100 shares of the stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $112.56, for a total transaction of $348,936.00. Following the completion of the transaction, the director now directly owns 9,050 shares of the company’s stock, valued at approximately $1,018,668. The disclosure for this sale can be found here. Insiders sold 242,210 shares of company stock valued at $28,840,232 in the last three months. Company insiders own 10.90% of the company’s stock.
UTHR has been the topic of several research reports. TheStreet cut United Therapeutics from a “b” rating to a “c” rating in a report on Wednesday. Credit Suisse Group boosted their price target on shares of United Therapeutics from $129.00 to $145.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Zacks Investment Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $128.00 price objective for the company in a report on Sunday, May 3rd. Wedbush reiterated a “buy” rating and issued a $244.00 price objective (up from $243.00) on shares of United Therapeutics in a report on Wednesday. Finally, HC Wainwright upped their price objective on shares of United Therapeutics from $85.00 to $125.00 and gave the stock a “neutral” rating in a report on Thursday, June 25th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $138.10.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Recommended Story: What is meant by holder of record?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.